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Abstract MicroRNAs (miRNAs) are small RNA mole-
cules that regulate gene expression post-transcriptionally.
After the discovery of the first miRNA in the roundworm
Caenorhabditis elegans, these short regulatory RNAs have
been found to be an abundant class of RNAs in plants,
animals, and DNA viruses. About 3% of human genes
encode for miRNAs, and up to 30% of human protein
coding genes may be regulated by miRNAs. MicroRNAs
play a key role in diverse biological processes, including
development, cell proliferation, differentiation, and apopto-
sis. Accordingly, altered miRNA expression is likely to
contribute to human disease, including cancer. This review
will summarize the emerging knowledge of the connections
between human miRNA biology and different aspects of
carcinogenesis. Various techniques available to investigate
miRNAs will also be discussed.
Keywords MicroRNA.miRNA.Cancer.Pathogenesis.
Development
The “small RNA revolution”
Small ribonucleic acid (RNA) can act as a specific regulator
of gene expression. This discovery has been an exciting
breakthrough in Biological Sciences of the past decade,
culminating in last year’s Nobel Prize in Physiology or
Medicine awarded to Andrew Fire and Craig Mello.
Building on previous work mainly in plants [50], Fire
et al. [23] discovered that exogenous double-stranded RNA
can be used to specifically interfere with gene function.
This phenomenon was called RNA interference (RNAi).
They also speculated that organisms might use double-
stranded RNA naturally as a way of silencing genes. It was
then shown that RNA interference was mediated by 22
nucleotide single-stranded RNAs termed small interfering
RNAs (siRNAs) derived from the longer double-stranded
RNA precursors [87]. The small interfering RNAs were
found to repress genes by eliminating the corresponding
messenger RNA transcripts, and thus, preventing protein
synthesis.
Over the following years, many new small functional
RNAs have been found. RNA is usually thought of as
messenger RNA that serves as the template for translation
of genes into proteins. In contrast, functional or non-coding
RNA molecules are transcribed from a DNA sequence, but
not translated into protein. The encoding DNA sequence is
often referred to as an RNA gene. Functional RNA genes in
the human genome include transfer RNA (tRNA), ribo-
somal RNA (rRNA), and various other small non-coding
RNAs. Several hundred genes in our genome encode small
functional RNA molecules collectively called microRNAs
(miRNAs). Precursors of these miRNA molecules form
structures of double-stranded RNA that can activate the
RNA interference machinery. MicroRNAs downregulate
Virchows Arch (2008) 452:1–10
DOI 10.1007/s00428-007-0532-2
S. Sassen (*):C. Caldas
Breast Cancer Functional Genomics Laboratory, Cancer Research
UK Cambridge Research Institute and Department of Oncology,
University of Cambridge, Li Ka Shing Centre,
Robinson Way,
Cambridge CB2 0RE, UK
e-mail: stefanie.sassen@cancer.org.uk
E. A. Miska
Wellcome Trust/Cancer Research UK Gurdon Institute
and Department of Biochemistry, University of Cambridge,
Cambridge, UKgene expression either by degradation of messenger RNA
through the RNA interference pathway or by inhibiting
protein translation.
The first miRNA was discovered in 1993 by Victor
Ambros and colleagues Rosalind Lee and Rhonda
Feinbaum [42]. A genetic screen in the roundworm
Caenorhabditis elegans, a millimeter-long animal used as
a model organism in biological research, identified genes
involved in developmental timing [42]. Surprisingly, one of
the genes, termed lin-4, did not encode a protein but instead
a novel 22-nucleotide small RNA. Seven years later,
Reinhart et al. [70] discovered a second 22-nucleotide
small RNA of this type, let-7, a gene also involved in
C. elegans developmental timing. The lin-4 and let-7 small
regulatory RNAs soon became very exciting for two
reasons. Firstly, homologs of the let-7 gene were identified
in other animals including humans [65]. The conservation
of let-7 across species suggested an important and
fundamental biological role for this small RNA. Secondly,
the mechanism of RNA interference (RNAi) was discov-
ered at that time, and it became clear that miRNA and
RNAi pathways were intricately linked and shared common
components. Within the following year, more than 100
additional small regulatory RNAs similar to lin-4 and let-7
were identified in worms, the fruit fly Drosophila, and in
humans [38, 40, 41]. These small non-coding RNAs were
named microRNAs (miRNAs) [38, 40, 41].
Subsequently, many more short regulatory RNAs were
identified in almost all multicellular organisms, including
flowering plants, worms, flies, fish, frogs, mammals [38,
40, 41, 48, 71], and in single cellular algae and DNA
viruses [66, 75]. To date, more than 500 human miRNAs
have been experimentally identified. Computational
predictions of miRNA targets suggest that up to 30% of
human protein coding genes may be regulated by miRNAs
[46, 68]. This makes miRNAs one of the most abundant
classes of regulatory genes in humans. MicroRNAs are now
perceived as a key layer of post-transcriptional control
within the networks of gene regulation.
MicroRNAs are sequentially processed from longer
precursor molecules that are encoded by the miRNA genes
[1] (Fig. 1). MiRNA genes are referred to by the same name
(termed mir) written in italics to distinguish them from the
corresponding mature miRNA (termed miR) followed by a
number, e.g., mir-1 or miR-1. The encoding DNA sequence
is much longer than the mature miRNA. Two ribonuclease
enzymes, Drosha and Dicer, subsequently process the
primary transcripts (or pri-miRNA) to generate mature
miRNAs. The primary transcripts contain one or more
stem-loop structures of about 70 bases. Stem-loops are
double-stranded RNA structures consisting of a nucleotide
sequence that can fold back on itself to form a double helix
with a region of imperfect base pairing that forms an open
loop at the end (Fig. 1a). The ribonuclease Drosha excises
the stem-loop structure to form the precursor miRNA (or
pre-miRNA) [43]. After export into the cytoplasm, the pre-
miRNA is cleaved by the ribonuclease Dicer to generate a
short RNA duplex [6, 28]. After untwisting, one RNA
strand becomes the mature single-stranded miRNA, while
the complementary strand, termed miRNA*, is usually
rapidly degraded (Fig. 1b).
MicroRNAs recognize their targets based on sequence
complementarity [10]. The mature miRNA is partially
complementary to one or more messenger RNAs. In
humans, the complementary sites are usually within the
3′-untranslated region of the target messenger RNA. To
become effective, the mature miRNA forms a complex with
proteins, termed the RNA-induced silencing complex. The
miRNA incorporated into the silencing complex can bind to
Fig. 1 The biogenesis and function of miRNAs. a Primary miRNAs
(pri-miRNA) are transcribed from longer encoding DNA sequences
(miRNA genes). The pri-miRNA contains one or more stem-loop
structures of about 70 bases. In the nucleus, the ribonuclease enzyme
Drosha excises the stem-loop structure to form the precursor miRNA
(pre-miRNA). b After export into the cytoplasm, the pre-miRNA is
cleaved by the ribonuclease Dicer to generate a short RNA duplex
(miRNA:miRNA*). c The mature single-stranded miRNA is incorpo-
rated into the RNA-induced silencing complex (RISC), while the
complementary strand (miRNA*) is usually rapidly degraded. The
miRNA incorporated into the silencing complex can bind to the target
messenger RNA by base pairing, causing inhibition of protein
translation and/or degradation of the target messenger RNA
2 Virchows Arch (2008) 452:1–10the target messenger RNA by base pairing. This base
pairing subsequently causes inhibition of protein translation
and/or degradation of the messenger RNA (Fig. 1c). The
potential mechanisms underlying this process were recently
reviewed [30, 67]. Protein levels of the target gene are
consequently reduced, whereas messenger RNA levels may
or may not be decreased. In humans, miRNAs mainly
inhibit protein translation of their target genes and only
infrequently cause degradation or cleavage of the messen-
ger RNA [1].
The biological role and in vivo functions of most
mammalian miRNAs are still poorly understood. In
invertebrates, miRNAs regulate developmental timing
(e.g., lin-4), neuronal differentiation, cell proliferation,
growth control, and programmed cell death [9, 33, 42]. In
mammals, miRNAs have been found to play a role in
embryogenesis and stem cell maintenance [7], hematopoi-
etic cell differentiation [17], and brain development [59,
60]. To date, knowledge of human miRNAs has been
primarily descriptive. MicroRNA expression has been
found to be deregulated in a wide range of human diseases
including cancer. However, it remains uncertain whether
altered miRNA expression is a cause or consequence of
pathological processes. The underlying mechanisms of why
and how miRNAs become deregulated are largely un-
known. Although bioinformatics approaches can predict
thousands of genes that are potentially targeted and
regulated by miRNAs based on sequence complementarity,
only very few miRNA target genes have been functionally
validated. Our group is currently investigating the role of
miRNAs in mammary gland development and breast cancer
pathogenesis. A comparison of miRNA and gene expres-
sion identified miRNAs that classify molecular breast
cancer subtypes [8]. As cancer is ultimately a consequence
of disordered gene expression, miRNAs have been sug-
gested to contribute to the development of cancer [11]. This
review will focus on the connection between human
miRNA biology and different aspects of carcinogenesis.
Various techniques available to investigate miRNAs will
also be discussed.
MicroRNAs and cancer
Three important observations early in the history of
miRNAs suggested a potential role in human cancer.
Firstly, the earliest miRNAs discovered in the roundworm
C. elegans and the fruit fly Drosophila were shown to
control cell proliferation and apoptosis [9, 42]. Their
deregulation may therefore contribute to proliferative
diseases such as cancer. Secondly, when human miRNAs
were discovered, it was noticed that many miRNA genes
were located at fragile sites in the genome or regions that
are commonly amplified or deleted in human cancer [14].
Thirdly, malignant tumors and tumor cell lines were found
to have widespread deregulated miRNA expression com-
pared to normal tissues [12, 24, 52]. The question remained
whether the altered miRNA expression observed in cancer
is a cause or consequence of malignant transformation.
MicroRNAs as causal cancer genes at genomic breakpoints
Five years ago, the first direct evidence for an involvement
of miRNAs in cancer was reported [13]. Calin et al. studied
a well-known deletion on chromosome 13, which is the
most frequent chromosomal abnormality in chronic lym-
phocytic leukemia (CLL). This deletion had long been
suspected to contribute to leukemogenesis. However,
extensive studies had failed to identify a causal gene. Calin
et al. [13] found that two miRNA genes, mir-15 and mir-16,
were located within this 30-kb deletion. They subsequently
analyzed the expression of miR-15 and miR-16 in blood
samples from patients with CLL. Both miRNAs were
absent or downregulated in the majority (68%) of cases
when compared to normal tissue or lymphocytes. This
finding suggested that these two miRNAs were causally
involved in the pathogenesis of chronic lymphocytic
leukemia.
In 2005, three reports provided the first mechanistic
insight into how miRNAs might contribute to carcinogen-
esis. Two independent studies described the relationship
between a miRNA cluster, mir-17-92, and the Myc
oncogenic pathway [27, 63]. A third report demonstrated
an interaction between let-7 miRNA and the RAS proto-
oncogene [32].
The mir-17-92 cluster—small RNAs with oncogenic
potential
A cluster of six miRNAs, the mir-17-92 cluster, was found
to be located within a region on chromosome 13 that is
commonly amplified in human B-cell lymphomas [64]. He
et al. [27] demonstrated that the miRNAs from the mir-17-
92 cluster were overexpressed in lymphoma cell lines
carrying this amplification, and expression levels correlated
with gene copy number of the mir-17-92 locus [27].
Further, the miR-17-92 primary transcript was found to be
overexpressed in tumor samples from lymphoma patients.
To test their hypothesis that mir-17-92 actively contributes
to lymphomagenesis, the authors took advantage of a
mouse model of human B-cell lymphoma. These mice
develop lymphomas due to an overexpression of the Myc
oncogene. The Myc oncogene encodes the transcription
factor c-Myc that regulates cell proliferation, growth, and
apoptosis, and overexpression of c-Myc is common in
cancer. He et al. [27] demonstrated that additional expres-
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tumorigenesis in mice. The authors therefore suggested that
mir-17-92 was the first potential non-coding oncogene,
referred to as oncomir-1.
The cellular function of miR-17-92 was not identified in
these experiments. Nevertheless, the pathology of the
tumors indicated lower rates of apoptosis as compared to
tumors with Myc overexpression alone. Three recent
studies contributed towards our understanding of the
oncogenic potential of miR-17-92. Two reports demonstrat-
ed an anti-apoptotic effect of miR-17-92 through various
pathways that promote cell proliferation and growth [55,
76]. A third study identified mir-17-92 as a mediator of
angiogenesis in tumors induced by the oncogene c-Myc
[19].
O’Donnell et al. [63] independently identified the same
cluster of miRNAs, mir-17-92, to be regulated by the
transcription factor c-Myc. The transcription factor Myc
induces expression of E2F1 growth factor. The mir-17-92
cluster which is also induced by c-Myc does, in contrast,
inhibit E2F1 expression. The authors therefore suggested a
novel regulatory mechanism by which c-Myc fine-tunes
gene expression by activating the transcription of target
genes and by simultaneously inducing inhibitory miRNAs
that reduce their translation.
The example of the mir-17-92 cluster highlights that a
distinction between oncogenic and tumor suppressor
miRNAs is likely to be an oversimplification. The same
miRNAs may have oncogenic or tumor suppressor activity
depending on the context and the cell type they are
expressed in. A single miRNA may regulate various
unrelated target genes and thereby control opposing
activities such as cellular proliferation and apoptosis. The
ultimate function of a miRNA may depend on the tissue
type they are expressed in and what target genes are
present.
MicroRNAs with tumor suppressor potential
The let-7 family of miRNAs was the first group of miRNAs
shown to regulate expression of a proto-oncogene, the RAS
protein. RAS proteins are membrane-associated signaling
proteins that regulate cell growth and differentiation. A
miRNA that controls expression of these potentially
oncogenic proteins would be predicted to possess tumor
suppressor activity.
Mutations in the RAS oncogene are present in approxi-
mately 15–30% of all human cancers, and overexpression of
the RAS oncogene is common in lung cancer. Johnson et al.
[32] showed that overexpression of RAS protein in lung
cancer tissue correlated with reduced expression of let-7
miRNA. They experimentally confirmed that let-7 can
inhibit RAS expression in human cancer cell lines. Loss or
reduction of let-7 in lung cancer leads to RAS over-
expression, thus, promoting cellular growth and contributing
to tumorigenesis. The authors therefore suggested that let-7
acts as tumor suppressor [32]. Another group independently
reported reduced expression of let-7 in lung cancers and
found that this correlated with a poor prognosis [77].
Global loss of miRNA expression in cancer
A global decrease in miRNA levels has been observed in
human cancers, indicating that small RNAs may have an
intrinsic function in tumor suppression. Lu et al. [52] were
the first to show that the expression levels of many
miRNAs were significantly reduced in cancers compared
to the corresponding normal tissues. They analyzed a total
of 217 human and mouse miRNAs across 334 human
cancers, cancer cell lines, and normal tissues. Cancers had
significantly reduced global miRNA expression. Poorly
differentiated tumors had lower miRNA levels compared
with more-differentiated tumors. The authors hypothesized
that miRNAs can function to drive terminal differentiation
and prevent cell division. Global changes in miRNA
expression may reflect the degree of cell differentiation
[52]. A recent study examined the expression of 241 human
miRNAs in a comprehensive panel of human cancer cell
lines, the NCI-60 panel, and in normal tissues [24]. The
authors confirmed the finding that most miRNAs were
expressed at lower levels in human tumor-derived cell lines
compared with the corresponding normal tissue [24].
Until recently, considerable uncertainty remained as to
whether the altered miRNA expression observed in cancer
was a cause or consequence of malignant transformation.
Earlier this year, a study by Kumar et al. [37] proved for the
first time that widespread reduction in miRNA expression
does, indeed, promote tumorigenesis. The authors globally
reduced the production of mature miRNAs through a
knockdown of the miRNA-processing enzymes Drosha
and Dicer in cell lines. The mouse and human cancer cells
consequently showed decreased steady-state miRNA levels.
These cells with global miRNA loss showed enhanced
cellular growth in vitro [37]. When injected into nude mice,
these cells generated faster growing and more invasive
tumors compared to controls. To assess the effect of global
miRNA loss in vivo, the authors deleted the miRNA-
processing enzyme Dicer in a mouse model of lung cancer.
The Dicer mutant mice who had impaired miRNA
processing developed an increased tumor burden, with an
expansion in tumor number and tumor size, as well as
tumors which were less well differentiated compared to
controls [37]. Overall, these data clearly suggest that global
miRNA loss enhances tumorigenesis. Kumar et al. demon-
strated that loss of miRNAs leads to upregulation of proto-
oncogenes such as RAS and c-Myc. However, it remains to
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whether reduction of a subgroup of key tumor suppressor
miRNAs, such as let-7,i st h ee v e n tt h a tp r o m o t e s
malignant transformation.
MicroRNAs in the p53 tumor suppressor network
Transcriptional networks are often deregulated in cancer
cells and may lead to altered transcription of miRNA genes.
Two recent studies identified a miRNA, miR-34, to be
regulated by the p53 transcription factor [16, 26]. The p53
protein, also called “the guardian of the genome”, regulates
the cellular response to stress and cancer-initiating events
such as DNA damage. He et al. [26] found that a miRNA,
miR-34, is directly activated by the transcription factor p53
after DNA damage. Expression of miR-34 induces cell
cycle arrest and thereby acts together with other effectors of
the p53 tumor suppressor network to inhibit inappropriate
cell proliferation. Another group independently demonstrat-
ed that miR-34 is upregulated by p53 upon DNA damage
and promotes apoptosis [16].
Together, these data indicate that altered expression of
miRNAs is not simply a secondary event that reflects the
less differentiated state of cancer cells. In contrast, at least
in some cases, miRNA expression is specifically driven by
tumor suppressors and oncogenes.
MicroRNAs with a role in tumor invasion and metastasis
Transcriptional networks may drive miRNA expression in
cancers. Recent work from Ma et al. [54] suggested a
model by which a pleiotropic transcription factor, Twist,
induces expression of a specific miRNA, which suppresses
its direct target and in turn activates a pro-metastatic gene,
leading to tumor cell invasion and metastasis. The
expression of miR-10b induced by the transcription factor
Twist promoted cell migration and invasion in mouse and
human breast cancer cells. Furthermore, the expression
level of miR-10b in primary human breast carcinomas
correlated with clinical progression [54]. These findings, if
confirmed, suggest that specific miRNAs may have a role
beyond the tumor-initiating event and directly participate in
tumor progression and metastasis.
Regulation of miRNAs in cancer—who regulates
the regulators?
In few cases, the underlying cause of miRNA deregulation
in cancer is clear. As discussed above, the overexpression
of miR-17-92 correlates with amplification of its gene locus
[27]. Similarly, decreased expression of miR-15 and miR-
16 is associated with a corresponding chromosomal
deletion [13].
Transcriptional or epigenetic regulation of miRNAs has
been recently reported [53, 73]. The transcription of a
miRNA gene, mir-124a, was shown to be inactivated by
hypermethylation of its promoter in various human tumors.
This process of epigenetic silencing is a well-known
mechanism to inactivate protein-coding genes in cancer cells
and may similarly apply to miRNAs. The miRNA gene mir-
127 is usually expressed in normal cells but not in cancer
cells. Saito et al. [73] demonstrated that miR-127 was highly
induced in cultured human cancer cells after treatment with
demethylating drugs, suggesting that it is subject to
epigenetic silencing through promoter hypermethylation.
A novel mechanism of miRNA regulation was suggested
by Mayr et al. [56] and Lee and Dutta [44]. They
demonstrated that miRNA function could be regulated
through loss of miRNA binding sites in the target gene.
Both groups independently demonstrated that chromosomal
translocations in a known oncogene, high mobility group
A2 (Hmga2), led to loss of the let-7 miRNA binding sites in
its messenger RNA. Disrupted repression of Hmga2 by
let-7 promoted oncogenic transformation and growth in
mammalian cells. These two studies provide the first
evidence that disrupting the interaction of a single miRNA
and its target can produce an abnormal phenotype in
mammalian cells [44, 56].
In addition, there is evidence that miRNAs are regulated
indirectly through control of their processing enzymes.
Thomson et al. [81] showed that a downregulation of
miRNAs in human cancer was not associated with reduced
levels of the primary miRNA transcripts. The authors
therefore suggested regulation of miRNAs during subse-
quent processing steps, e.g., through altered function of the
enzyme Drosha [81].
MicroRNA profiling—implications for cancer diagnosis
Lu et al. [52] asked the question whether global miRNA
expression profiles could classify human cancer. Micro-
RNA expression profiles clearly differentiated human
cancers according to their developmental origin.
Cancers of epithelial and hematopoietic origin had
distinct miRNA profiles. A subgroup of gastrointestinal
tumors, which arise from endoderm, was distinguished by
miRNA expression patterns. Furthermore, tumors within a
single cell lineage such as acute lymphoblastic leukemia
were further differentiated according to their underlying
genetic abnormality into BCR/ABL-positive tumors, T-cell
tumors, and those with MLL gene rearrangement [52].
Finally, the authors applied the miRNA expression profiles
they had established to an independent series of 17 poorly
differentiated tumors of unknown origin. Based on the
differential expression of 217 miRNAs, a correct diagnosis
could be established in 12 out of 17 of the tumors. In
Virchows Arch (2008) 452:1–10 5contrast, gene expression profiling based on ∼16,000
messenger RNAs did not accurately classify the tumors
[52]. This has potential important clinical implications. If
miRNAs prove useful for clinical diagnosis, their key
advantage might be their high stability. In contrast to most
messenger RNAs, they are long-lived in vivo [49] and very
stable in vitro [78], which might allow analysis of paraffin-
embedded samples for routine diagnostic applications.
MicroRNAs—novel therapeutic targets?
Regulatory RNAs may also have therapeutic applications by
which disease-causing miRNAs could be antagonized or
functional miRNAs restored. The most intuitive choice of
molecules to correct altered miRNA–messenger RNA inter-
actions are RNA oligonucleotides. These oligonucleotides
need to be chemically modified to allow for stability in serum
and cellular uptake. Modified antisense oligonucleotides are
already being developed to utilize the intrinsic RNAi pathway
for delivery of gene therapy. If the delivery problem can be
overcome, then miRNA therapies may also be possible.
Two studies have successfully applied 2′-O-Methyl-
modified antisense RNAs to inhibit miRNA function in
cultured cells [29, 57]. Recent work by Krutzfeldt et al. [36]
demonstrated that modified cholesterol-conjugated anti-
sense RNAs designated “antagomirs” could effectively
inhibit miRNA function in vivo in the adult mouse. The
authors applied three daily intravenous injections of
antagomirs and achieved effective inhibition of four
miRNAs over a period of weeks in most tissues except
brain [36]. A novel approach was recently reported by
Ebert et al. [21]. They developed miRNA inhibitors that
can be transiently expressed in cultured mammalian cells.
These competitive inhibitors termed “miRNA sponges”
derepressed miRNA targets at least as strongly as chemi-
cally modified antisense oligonucleotides [21]. A different
approach was taken by Tsuda et al. [83]. The authors
designed synthetic miRNAs to target overexpressed tumor
proteins, such as HER-2 protein. A synthetic miRNA
targeting HER-2 messenger RNA successfully inhibited
HER-2 protein expression in ovarian cancer cells [83].
Together, these studies hold some promise of miRNAs as
future therapeutic targets.
One limitation of antisense RNA therapies is the
restricted number of cells that can be targeted. Any
approach to knock down a particular miRNAwith antisense
oligonucleotides will only result in partial knockdown. This
may represent a limitation for cancer therapies. It remains
to be seen whether indirectly mediated bystander effects on
cancer cells that have not been directly targeted may partly
overcome this limitation. In contrast, a partial effect on
function may be of therapeutic value in neurodegenerative
diseases, such as Parkinson’s or Alzheimer’s disease. A
partial restoration of dopamine production by antisense
therapy might result in a significant clinical improvement in
Parkinson patients. Similarly, a partial reduction of the
disease-causing proteins in Alzheimer’s disease may lead to
a clinical improvement and might be achievable by RNA
based or miRNA gene therapy.
Techniques and approaches to study miRNAs
All known miRNAs are registered in a public web-based
registry, the “miRBase” database that provides up-to-date
information on all published miRNAs [25]. Novel miRNA
genes can be discovered by bioinformatics approaches
searching for evolutionary conserved stem-loop structures
in the genome (reviewed in [3, 5]). Experimentally,
miRNAs are discovered by cloning all small RNAs from
a certain tissue type or developmental stage and subsequent
sequencing to identify the subgroup of small RNAs that
fulfill the criteria for miRNAs [38, 51]. Both computational
and experimental approaches indicate that many more
miRNAs are likely to be identified [4, 5], which is reflected
by the rapidly increasing number of annotated miRNAs
which increased from less than 300 to more than 4,000 over
the past 4 years [58].
MicroRNA expression studies
Northern blot analysis is a well-established technique for
studying messenger RNA expression and was soon adapted
to detect miRNAs in cells or tissues [42, 84]. Subsequently,
conventional DNA microarray technology was modified to
form miRNA microarrays, allowing for the detection of
multiple miRNAs simultaneously across various samples
[15, 60, 62, 82].
Lu et al. [52] developed a novel microarray strategy to
improve probe specificity, which is critical due to the short
nature of mature miRNAs. They performed hybridization in
solution using polystyrene capture beads that are coupled to
oligonucleotide probes complementary to the miRNAs of
interest. The solution hybrids are then analyzed using a
multicolor flow cytometer measuring bead color, denoting
miRNA identity, and labeling intensity, denoting miRNA
abundance [52].
In parallel to microarray platforms, commercial assays
for quantitative reverse transcriptase polymerase chain
reaction (RT-PCR) have become available. These allow
for the analysis of miRNAs in small tissue samples or even
single cells [79], as well as validation of microarray data. In
addition to mature miRNAs, these quantitative RT-PCR
assays can be applied to analyze miRNA precursors and
primary transcripts [31]. In situ hybridization for the
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by using special high-affinity locked nucleic acid (LNA)-
modified DNA oligonucleotide probes and holds promise
for the application on human formalin-fixed and paraffin
embedded tissue [35, 61].
Functional characterization of miRNAs
Various strategies have been used to investigate the
function of specific miRNAs. In worms and flies, loss-of-
function mutants for specific miRNAs or miRNA families
allow us to draw conclusions regarding possible physio-
logical functions of miRNAs from the resulting abnormal
phenotype [34, 39, 86]. The knockdown of miRNAs or pre-
miRNAs using modified antisense oligonucleotides has
proven particularly useful in cell lines [29, 45, 57]. LNA-
modified antisense oligonucleotides have been successfully
utilized to knock down specific miRNAs in cultured cells
[22]. This approach allowed identification of a crucial role
for a miRNA, miR-223, in granulocytic differentiation [22].
In addition, the modified antisense RNAs (antagomirs)
described by Krutzfeldt et al. [36], which inhibit miRNA
function in the adult mouse, may provide a potential
research tool to study miRNA function in vivo.
In mammals, induced defects in miRNA biogenesis are a
useful tool for investigating the biological roles of miRNAs,
as loss-of-function mutants are not available for most miRNA
genes. Dicer knockout mouse models have revealed essential
roles for miRNAs in murine organogenesis [88]. A recent
study utilized a combined knockdown of the miRNA-
processing enzymes Drosha, Dicer1, and DGCR8 to study
the consequences of a global decrease in mature miRNAs in
cancer cell lines and in a mouse model for lung cancer [37].
Earlier this year, four independent groups have, for the
first time, deleted genes for single miRNAs in mice [72, 80,
85, 88]. Two of the groups deleted the same DNA sequence
for mir-155 and described severe immune defects [72, 80].
Mice lacking miR-155 showed impaired function of B and
T lymphocytes and dendritic cells [72]. In particular, T
helper cell differentiation and the germinal center reaction
to produce a T-cell-dependent antibody response were
defective [80]. Together, these two studies demonstrated a
key role for miR-155 in normal immune function. The two
other groups deleted different miRNAs, miR-1-2 and miR-
208, and reported cardiac defects. Mice lacking miR-208
showed inadequate cardiac growth in response to stress
[85], while mice lacking miR-1-2 had defects in cardiac
morphogenesis and electrical conduction [88].
MicroRNA target sites
A validated biochemical strategy for identifying miRNA
targets would be highly desirable. Two groups have
recently reported promising approaches to experimentally
identify miRNA targets. Both approaches apply biochem-
ical methods to purify the effector complexes of miRNAs
associated with proteins and bound messenger RNA targets
[2, 20].
An increasing number of sophisticated bioinformatics
approaches are being developed to predict putative miRNA
target genes [3, 10, 69, 74]. This is based on the fact that
miRNA target recognition is at least partly based on simple
sequence complementarity. Interestingly, exact base pairing
between miRNAs and their targets commonly appears to be
required only in the first six to eight bases from the 5′ end
of the miRNA. The short nature of this designated “seed
region” allows a single miRNA to act on up to a hundred
different target sites, and all human miRNAs together may
regulate up to one third of protein coding genes [10, 47]. A
different approach to discovering miRNA target genes is to
knock out or overexpress a particular miRNA and use
conventional microarrays to identify genes that show
changes in expression. This approach is based on the
observation that some miRNAs can also downregulate
messenger RNA levels in addition to downregulating
protein levels of their target genes [49]. Experimental
validation of miRNA target sites has been limited to date.
A common approach has been to express a miRNA in vivo
while simultaneously expressing and monitoring the target
messenger RNA linked to a reporter gene, i.e., Luciferase
[10, 18, 55, 56, 76]. The fact that a single miRNA can
regulate multiple targets and a particular target may be
regulated by various miRNAs suggests a highly complex
network of miRNA-target interactions, which is only
beginning to be unraveled.
Conclusions
Over recent years, miRNAs have emerged as major players
in the complex networks of gene regulation and have been
implicated in various aspects of human disease. Only
5 years after the first study reported a direct involvement
of miRNAs in cancer, these small RNAs have already
significantly improved our understanding of carcinogenesis.
In addition to protein-coding oncogenes and tumor sup-
pressor genes, we will have to take into account miRNAs
and their regulatory networks if we aim to understand the
complex processes underlying malignant transformation.
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